Antisense Therapeutics Limited (AU:PER) has released an update.
Percheron Therapeutics Limited has reported a 4.7% increase in its annual loss to $11,919,223 for the fiscal year ending June 30, 2024, primarily due to costs associated with advancing their phase IIb clinical trial for Duchenne muscular dystrophy. The company also noted a decrease in net tangible assets per share from $1.47 to $1.03, and confirmed that no dividends have been paid or declared during this period.
For further insights into AU:PER stock, check out TipRanks’ Stock Analysis page.
